Clinical Trial Update: Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating an all-oral combination of clarithromycin and lenalidomide for relapsed or refractory mucosa-associated lymphoid tissue lymphoma; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Marginal Zone Lymphoma
• Mucosa-associated Lymphoid Tissue Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• clarithromycin (clarithromycin)

Snippet

Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Conditions: Mucosa Associated Lymphoid Tissue (MALT) Lymphoma | Phase 2 | Status: COMPLETED